Discover our initiatives in various therapeutic areas
Carfilzomib SPC® is used to treat adult patients with multiple myeloma who
have had at least one previous treatment for this disease.
Strength:
60 mg
Dosage Form:
Vial for injection.
Active ingredient:
Carfilzomib
Bortezomib SPC® is indicated for the treatment of:
Multiple myeloma (MM).
-alone or together with the medicines pegylated liposomal doxorubicin or dexamethasone, forpatients whose disease is worsening (progressive) after receiving at least one prior treatmentand for whom blood stem cell transplantation was not successful or is unsuitable
– in combination with the medicines melphalan and prednisone, for patients whose diseasehas not been previously treated and are unsuitable for high-dose chemotherapy with bloodstem cell
transplantation
– in combination with the medicines dexamethasone or dexamethasone together withthalidomide, for patients whose disease has not been previously treated and before receivinghigh-dose chemotherapy with blood stem cell transplantation (induction treatment).
Strength:
3.5 mg
Dosage Form:
Powder for Solution for Injection
Active ingredient:
Bortezomib
Pomalidomide SPC is used to treat adults with a type of cancer called ‘multiple myeloma’ Pomalidomide SPC is either used with:
‘dexamethasone’ (an anti-inflammatory medicine) in people who have had at least one
other treatment – including lenalidomide.
Or
worse, despite having at least two other treatments – including lenalidomide and bortezomib.
Strength:
1 mg
2 mg
3 mg
4 mg
Dosage Form:
Capsule
Active ingredient:
Pomalidomide
Lenalidomide SPC® is used in adult for:
Strength:
5 mg
10 mg
15 mg
20 mg
25 mg
Dosage Form:
Capsule
Active ingredient:
Lenalidomide